Associazione Nazionale Medici Cardiologi Ospedalieri

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
LDL target in patients with HIV at high cardiovascular risk: the role of bempedoic acid
Anno:
2024
Background: Previous observational studies have shown that 70% of HIV-infected patients have clinical conditions that classify them at high or very high cardiovascular risk. Among these patients, only 12% succeed in achieving a target LDL < 55 mg/dl in accordance with the latest ESC guidelines. Aim: To evaluate the...
MULTIDRUG RESISTANT DYSLIPIDEMIA: A CASE REPORT
Anno:
2024
Introduction: Recently introduced lipid-lowering agents (PCSK9-i, bempedoic acid) can efficiently treat statin-intolerant patients, who couldn ‘t reach LDL target before. Nonetheless, there are still cases where the pharmacological management may have strong limitations. Case report: A 71 year-old woman, with multiple cardiovascular risk factors (diabetes, hypertension and familial dylipidemia,…
Carotid plaques treated with Bembedoic acid: a 7% of reduction in 6 months
Anno:
2024
Bempedoic acid were indicated to be able to reduce the hypercholesterolemia add on to statin and ezetimibe therapy. We investigated the effect of the same treatment in carotid atherosclerosis after a follow up of 6 months. Methods A continuous series of 22 patients were enrolled in a prospective analysis….